MXB 22510
Alternative Names: MXB-22,510Latest Information Update: 18 Jan 2024
At a glance
- Originator Maxwell Biosciences
- Class Anti-infectives; Antivirals; Peptoids
- Mechanism of Action Viral envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS infections; Mycoses; Rhinosinusitis; Viral infections
Most Recent Events
- 18 Jan 2024 Maxwell Biosciences plans a clinical trial in 2024 (Maxwell Biosciences website, January 2023)
- 02 Jan 2024 Preclinical trials in CNS infections in USA (Intranasal) (Maxwell Biosciences website, January 2023)
- 02 Jan 2024 Preclinical trials in Mycoses in USA (Intranasal) (Maxwell Biosciences pipeline, January 2023)